Arguably, lung transplantation is becoming a less attractive treatment recommendation for COPD, mainly because the survival benefit has been questioned11 and newer approaches to medical management continue to improve patient-reported outcomes. The long-acting inhaled bronchodilators fall into two classes: long-acting muscarinic antagonists (LAMAs) and long-acting -2 sympathomimetic agonists (LABAs). Rabbit Continue Reading